Fairfax, Virginia - Fifty-seven percent of lung cancer patients who were treated with thermal ablation survived to three years, two years beyond average life expectancy, according to research in the July issue of the Journal of Vascular and Interventional Radiology (JVIR). The patients had early-stage, I-II, non-small cell lung cancer (NSCLC). During thermal ablation, an interventional radiologist uses imaging to guide a small needle through the skin into the tumor. Energy is then transmitted to the tip of the needle to "cook" and kill the tumor with heat or "freeze" it with cold.

"Only one-third of patients diagnosed with non-small cell lung cancer are eligible for surgery - the rest face the reality of having less than 12 months to live," states study author Damian Dupuy, M.D., of Rhode Island Hospital. "These new outpatient treatments not only are effective, but allow us to treat patients who historically have no other options. Utilizing imaging and targeted thermal ablation, we can heat and destroy lung tumors, and extend a patients life. As a physician, it's so gratifying to be able to provide a treatment that is so beneficial to patients and so easy for them to undergo."

The purpose of this study was to evaluate the clinical outcomes of patients with early-stage NSCLC after combined treatment with thermal ablation and radiotherapy, and it showed that the combination therapy may result in an improved survival over either modality alone.


About the Study

The patients in the study were terminal, with a life expectancy of less than one year, and were not surgical candidates according to the oncology team which consisted of a pulmonologist, medical
oncologist, radiation oncologist and thoracic surgeon. Twenty-seven of the patients who underwent thermal ablation subsequently received external-beam radiation, the primary treatment in patients who are considered poor operative candidates. Fourteen patients underwent thermal ablation followed by interstitial brachytherapy, which is radiation therapy given internally to the tumor with a catheter. Of the 41 patients, 97.6% survived to six months, 86.8% to one year, 70.4% to two years and 57.1% to three years. The median follow-up was 19.5 months with an average survival of 42.2 months. The patients with tumors smaller than 3 cm (n=17) had the best outcomes, with an average survival of 44.4 months.

About Thermal Ablation

Tumors need a blood supply, which they actively generate, to feed themselves and grow. As vascular
experts, interventional radiologists are uniquely skilled in using the vascular system to deliver targeted treatments via catheter throughout the body or percutaneously through the skin. In treating cancer patients, interventional radiologists can attack the cancer tumor from inside the body without medicating or affecting other parts of the body. These minimally-invasive treatments are much easier on the patient than systemic therapy. Thermal ablation can be given without affecting the patient's overall health and most people can resume their usual activities in a few days. The treatment usually does not require general anesthesia and is typically performed on an outpatient basis. Thermal ablation treatments are a growing area in interventional oncology, a specialty area of medicine within interventional radiology. In this study, the two types of thermal ablation used were radiofrequency and microwave.

More Industry Headlines